Tumor suppressor genes

The Molecular Basis of Cancer

Volumn , Issue , 2008, Pages 31-38

  Levine, Arnold J ^a,b   Hu, Wenwei ^a,b   Feng, Zhaohui ^a,b  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 59849125732     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141603703-3.10003-2     Document Type: Chapter

References (39)

1. Bishop JM Cellular oncogenes and retroviruses. Ann Rev Biochem 1983, 52:301.
2. Harris SL, Gil G, Robins H, et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci U S A 2005, 102:16297.
3. Levine AJ Tumor suppressor genes. The Molecular Basis of Cancer 1995, 86. WB Saunders, Philadelphia. J. Mendelsohn (Ed.).
4. Harris H Cell fusion and the analysis of malignancy. Proc R Soc Lond B Biol Sci 1971, 179:1.
5. Knudson AG Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001, 1:157.
6. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986, 323:643.
7. Cavenee WK Tumor progression stage: specific losses of heterozygosity. Princess Takamatsu Symp 1989, 20:33.
8. Lee WH The molecular basis of cancer suppression by the retinoblastoma gene. Princess Takamatsu Symp 1989, 20:159.
9. Finlay CA, Hinds PW, Levine AJ The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989, 57:1083.
10. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989, 244:217.
11. Levine AJ, Momand J Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products. Biochim Biophys Acta 1990, 1032:119.
12. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129.
13. Weinberg RA Tumor suppressor genes. Science 1991, 254:1138.
14. Fearon ER Human cancer syndromes: clues to the origin and nature of cancer. Science 1997, 278:1043.
15. Offit K BRCA mutation frequency and penetrance: new data, old debate. J Natl Cancer Inst 2006, 98:1675.
16. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591.
17. Vogelstein B, Lane D, Levine AJ Surfing the p53 network. Nature 2000, 408:307.
18. Harris SL, Levine AJ The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899.
19. Bond GL, Hu W, Levine AJ MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005, 5:3.
20. Zhao R, Gish K, Murphy M, et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000, 14:981.
21. Robins H, Alexe G, Harris H, Levine AJ The first twenty-five years of p53 research. Twenty-Five Years of p53 Research 2005, 1. Springer, Dordrecht. P. Hainaut, K.G. Wiman (Eds.).
22. Lahav G, Rosenfeld N, Sigal A, et al. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet 2004, 36:147.
23. Sherr CJ, Bertwistle D, DEN Besten W, et al. p53 dependent and independent functions of the Arf tumor suppressor. Cold Spring Harb Symp Quant Biol 2005, 70:129.
24. Lohrum MA, Ashcroft M, Kubbutat MH, et al. Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. Curr Biol 2000, 10:539.
25. Levine AJ, Feng Z, Mak TW, et al. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006, 20:267.
26. Yue Z, Jin S, Yang C, et al. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A 2003, 100:15077.
27. Aita VM, Liang XH, Murty VV, et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 1999, 59:59.
28. Feng Z, Zhang H, Levine AJ, et al. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005, 102:8204.
29. Feng Z, Hu W, de Stanchina E, et al. The regulation of AMPK 1, TSC2 and PTEN expression by p53: stress, cell and tissue specificity and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 2007, 67. in press.
30. Bougeard G, Baert-Desurmont S, Tournier I, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006, 43:531.
31. Ruijs MW, Schmidt MK, Nevanlinna H, et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007, 15:110.
32. Tang MS, Pfeifer GP, Denissenko MF, et al. Mapping polycyclic aromatic hydrocarbon and aromatic amine-induced DNA damage in cancer-related genes at the sequence level. Int J Hyg Environ Health 2002, 205:103.
33. Olivier M, Hussain SP, Caron de Fromentel C, et al. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 2004, 157:247.
34. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002, 19:607.
35. Zhang X, Miao X, Guo Y, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006, 27:1106.
36. Jin S, Martinek S, Joo WS, et al. Identification and characterization of a p53 homologue in Drosophila melanogaster. Proc Natl Acad Sci USA 2000, 97:7301.
37. Schumacher B, Hofmann K, Boulton S, et al. The C. elegans. Curr Biol 2001, 11:1722.
38. Gottlieb E, Haffner R, King A, et al. Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. Embo J 1997, 16:1381.
39. Jacks T Tumor suppressor gene mutations in mice. Ann Rev Genet 1996, 30:603.